Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

Phase 2 Recruiting 14 enrolled University of California, Irvine

NaSingle-groupOpen-labelTreatment

This is a phase 2, single-arm, open label clinical trial determining efficacy of Cyclophosphamide and Pembrolizumab in subjects with melanoma.

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	50 mg	Oral
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous
Subject	Pembrolizumab	Monoclonal antibody	400 mg	Intravenous